Straits Times Index
3,330.01 -8.93 (-0.27%) S&P 500
5,354.03 +62.69 (+1.18%) Dow
38,807.33 +96.04 (+0.25%) Nasdaq
17,187.90 +330.86 (+1.96%) Bitcoin USD
71,127.73 +390.86 (+0.55%) CMC Crypto 200
1,524.78 +51.04 (+3.46%)
PFE Aug 2024 33.000 call
- Associated Press Finance
FDA advisers urge targeting JN.1 strain in recipe for fall's COVID vaccines
Government advisers Wednesday said it’s time to update the recipe for the COVID-19 vaccines Americans will receive in the fall -- targeting a version of the ever-evolving coronavirus called JN.1. Moderna, Pfizer and Novavax all have tested doses updated to match the JN.1 variant that became dominant last winter. FDA’s advisers voted Wednesday that the next vaccine should come from the JN.1 “lineage” or family.
- GlobeNewswire
Relay Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Atirmociclib in Combination with RLY-2608
Initial triplet combination of RLY-2608 + atirmociclib + fulvestrant to be evaluated in patients with PI3Kα-mutated HR+/HER2- metastatic breast cancer; initiation planned by end of 2024CAMBRIDGE, Mass., June 05, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced a clinical trial collaboration with Pfizer Inc. (NY
- Benzinga
Promising Trial Results Show New Standards In Cancer Treatment And Diagnostics Are On The Horizon
On Friday, Pfizer Inc (NYSE: PFE) revealed its drug for an advanced form of lung cancer showed promising long-term results in a late-stage trial. On Monday, Moderna (NASDAQ: MRNA) and Merck & Co (NYSE: MRK) also reported durable efficiency of their combined melanoma treatment that consists of an experimental mRNA vaccine and Merck’s blockbuster immunotherapy, Keytruda. Pfizer Is Aiming To Set The Treatment Standard For Lung Cancer With encouraging results, Pfizer is getting another step closer t
